Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5320_Библиотеки_им_академика_М_И_Перельмана
.pdf
https://t.me/med1917
276
Pharmaceutical Dosage Forms and Drug Delivery
FIGURE 15.7
®®
®
In vitro
Int. J. Pharm
containing chitosan, succinic acid, and Eudragit®
(a). In vitro
®®
T
c).
15.7.1 Kidney- Targeted Drug Delivery
https://t.me/med1917
Organ-Specic Drug Delivery
277
15.7.1.1 Cellular Drug Targets
macromolecules.
-
ease to end- stage renal disease. It involves changes in the renal vasculature, glomerulosclerosis, and
targeting.
15.7.1.2 Particulate Systems
https://t.me/med1917
278
Pharmaceutical Dosage Forms and Drug Delivery
2
in vitro and in vivo on intravenous administration. Administration
of immunoliposomes.
in vitro
in vitro
15.7.1.3 The Prodrug Approach
https://t.me/med1917
Organ-Specic Drug Delivery
279
N
in humans.
N
N
conversion of the prodrug to the active compound.
15.7.1.4 Bioconjugation Approaches
the biopharmaceutical properties of the carrier to dominate the absorption and biodistribution of the
https://t.me/med1917
280
Pharmaceutical Dosage Forms and Drug Delivery
(
tubular cells. In vitro
N
https://t.me/med1917
Organ-Specic Drug Delivery
281
FIGURE 15.8
tubular cells (3) through the megalin receptor ( ) is
Int. J. PharmKidney Int
Biomaterials
Review Questions
not
A
B Sublingual absorption of a drug
C
D
https://t.me/med1917
282
Pharmaceutical Dosage Forms and Drug Delivery
not a barrier to the absorption of lipophilic molecules across the epi-
A
B
C
D
A
B
C
D Epithelial cells
A Retrobulbar route
B Intravitreal route
C Subtenon route
D
A
B Ester bonds
C Ether bonds
D Amide bonds
not-
A Enteric coating
B Osmotic pump- based sustained drug release
C
D
not
A
B
C
D
A
B Micelles
C
D Prodrugs
A
B
C
D Incorporation in a micelle
https://t.me/med1917
Organ-Specic Drug Delivery
283
not depend on the concentration gra-
A
B Drug absorption across the sublingual tissue
C
D
FURTHER READINGS
-
Biochem Pharmacol 62
Pharm Res 16
to glomerular endothelium. Mol Pharmacol 72
AAPS PharmSciTech
10
J Drug
Target 2
-
Int J Pharm 95
Br J Clin Pharmacol
31
Eur J Biochem/ FEBS
255
J Med Chem 26
Eur J Pharm Biopharm 70
Lancet 365
Renal clearance of quantum dots. Nat Biotechnol 25
J
Pharm Pharm Sci 6
Drug Deliv
11
Int Rev Cytol 180
development. Pediatr Nephrol 17
-
J Pharm
Pharmacol 42
-
tine. Gut 27
Int J Pharm 364
https://t.me/med1917
284
Pharmaceutical Dosage Forms and Drug Delivery
prodrugs. II. Carrier- mediated transport and intracellular conversion as determinants in the renal select-
J Pharmacol Exp Ther 252
Br J Pharmacol 99
J Med Chem 35
Pharm Res
10
Eur J
Pharm Biopharm 72
J Biol Chem 275
Int
J Pharm 204
J Control Release 117
J Control Release 110
-
Pharm Res 25
targeting. Expert Opin Drug Deliv 3
Lancet 361
Drug Deliv 7
Cardiovasc
Drugs Ther 16
Kidney Int 52
protein handling in the intact rat. Kidney Int 43
Pharm Res 15
J Control Release 62
drugs. Crit Rev Ther Drug Carrier Syst 19
Regional differences in quinine absorption from the undisturbed human colon assessed using a timed
Pharm Res 16
Int
J Pharm 370
https://t.me/med1917
Organ-Specic Drug Delivery
Crit Rev
Ther Drug Carrier Syst 13
dogs. J Control Release 56
J Pharm Pharmacol 52
-
Arc Biochem Biophys 368
Expert Opin Drug Deliv 5
FS30D- coated colon- targeted pellets of indomethacin. J Drug Target 15
J Biomater Appl 23
J Clin Pharmacol 39
J Control Release 52
J Control
Release 54
-
Int J Pharm 139
and its application for renal drug targeting. Nat Biotechnol 21
Int J Pharm 366
Bisacodyl dosage form with multiple enteric polymer coatings
for colonic delivery
Eur J
Nucl Med Mol Imaging 29
Biomaterials 25
J Pharmacol Exp Ther
288
Crit Rev Food Sci Nutr 45
Curr Drug Deliv
5
Biol Pharm Bull 28
-
minergic prodrug in man. J Auton Pharmacol 10
-
in vitro investigation. Int J Pharm 332
Drug Deliv 12
Eur J Pharm Biopharm 72
Соседние файлы в папке Библиотека им академика М.И. Перельмана